16
1
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T39222 |
Mc-VC-PAB-SN38
Mc-VC-PAB-SN38 |
Others; Drug-Linker Conjugates for ADC | Antibody-drug Conjugate/ADC Related; Others |
Mc-VC-PAB-SN38 由可降解 (cleavable) 的 ADC linker (Mc-VC-PAB) 和 SN38 组成,属于抗体偶联活性分子的一部分,常用来合成靶向作用位点的抗体偶联活性分子 (ADC)。 | |||
T38962 |
MC-SN38
MC-SN38 |
Others; Drug-Linker Conjugates for ADC | Antibody-drug Conjugate/ADC Related; Others |
MC-SN38 is a drug-linker conjugate that pairs the potent microtubule-disrupting agent SN38 with a non-cleavable MC linker, designed for use in antibody drug conjugates (ADCs). SN38, the active metabolite of the Topoisomerase I inhibitor Irinotecan, works by inhibiting DNA synthesis and inducing DNA single-strand breaks. | |||
T38474 |
CL2-MMT-SN38
CL2-MMT-SN38 |
Others | Others |
CL2-MMT-SN38 is a derivative of SN-38, which is a potent anticancer agent and the active metabolite of Irinotecan (CPT-11), a Topoisomerase I inhibitor. | |||
T17731 |
CL2A-SN-38
CL2A SN 38,CL2A-SN38 |
Others; Drug-Linker Conjugates for ADC | Antibody-drug Conjugate/ADC Related; Others |
CL2A-SN-38 由CL2A链接子和抗癌化合物SN-38 组成,可在肿瘤细胞内和肿瘤微环境中递送活性活性分子,通常会与抗体制成具有生物活性的抗体偶联活性分子 (ADC)。 | |||
T25593 |
Labetuzumab govitecan
IMMU-130,Labetuzumab-SN38,hMN14-SN38,IMMU130,IMMU 130 |
Others; Antibody-Drug Conjugates (ADCs) | Antibody-drug Conjugate/ADC Related; Others |
Labetuzumab govitecan is an anti-CEACAM5/SN-38 antibody-drug conjugate for therapy of refractory or relapsing metastatic colorectal cancer. | |||
T77882 |
SN38-COOH
|
Others; Drug-Linker Conjugates for ADC | Antibody-drug Conjugate/ADC Related; Others |
SN38-COOH 是合成抗体-活性分子偶联物 (ADC) 的关键中间体。SN-38 作为伊立替康的活性代谢物,主要功能是抑制拓扑异构酶 I,从而阻碍 DNA 和 RNA 的合成。 | |||
T82710 |
CL2E-SN38
|
Others; Drug-Linker Conjugates for ADC | Antibody-drug Conjugate/ADC Related; Others |
CL2E-SN-38为结构稳定的抗体与SN-38偶联物,属于抗体药物偶联物(ADC)。SN-38作为Irinotecan在喜树碱中的活性代谢产物,充当拓扑异构酶I抑制剂。 | |||
T77837 |
CL2E-SN38 TFA
|
Others; Drug-Linker Conjugates for ADC | Antibody-drug Conjugate/ADC Related; Others |
CL2E-SN-38 TFA为一抗体-SN-38稳定偶联体,属抗体药物偶联物(ADC)范畴。SN-38是Irinotecan活性代谢产物,源自喜树碱,作为拓扑异构酶I的抑制剂。 | |||
T21331 |
SAR-020106
|
Chk | Cell Cycle/Checkpoint |
SAR-020106 是一种强效、ATP 竞争性和选择性 CHK1 抑制剂,IC50为 13.3 nM。它对 CHK2 具有良好的选择性,可通过选择抗癌药物增强抗肿瘤活性。 | |||
T81143 |
SN38-PAB-Lys(MMT)-oxydiacetamide-PEG8-N3
|
Others; Drug-Linker Conjugates for ADC | Antibody-drug Conjugate/ADC Related; Others |
SN38-PAB-Lys(MMT)-oxydiacetamide-PEG8-N3 是一款用于抗体药物偶联物 (ADC) 合成的化学试剂,由抗癌药物SN38与链接子Lys(MMT)-PAB-oxydiacetamide-PEG8-N3 构成,属于点击化学工具。该化合物含有Azide基团,它可通过铜催化的叠氮-炔点击反应 (CuAAc) 与含Alkyne基团的分子耦合,亦能通过应变促进的炔-叠氮点击反应 (SPAAC) 与含DBCO 或 BCN 基团的分子反应。 | |||
T18538 |
MAC glucuronide phenol-linked SN-38
|
Others; Drug-Linker Conjugates for ADC | Antibody-drug Conjugate/ADC Related; Others |
MAC glucuronide phenol-linked SN-38, a pH-sensitive lactone and DNA topoisomerase I inhibitor drug linker, exhibits cytotoxicity in L540cy and Ramos cells, with IC50 values of 113 ng/mL and 67 ng/mL, respectively[1]. | |||
T18722 |
MAC glucuronide α-hydroxy lactone-linked SN-38
|
Others; Drug-Linker Conjugates for ADC | Antibody-drug Conjugate/ADC Related; Others |
MAC glucuronide α-hydroxy lactone-linked SN-38 (Topoisomerase I inhibitor) is a stabilized lactone MAC glucuronide α-hydroxy lactone-linked SN-38 drug linker. MAC glucuronide α-hydroxy lactone-linked SN-38 is cytotoxic across L540cy cells and Ramos cells | |||
T70380 |
ZBH-1205
|
Others | Others |
ZBH-1205 is a novel camptothecin derivative, revealing potent antitumor activities mainly through cell apoptosis pathway, being more effective than cpt-11 and sn38 at inhibiting topoismerase-1 | |||
T13191 |
TP3011
CH0793011 |
Others | Others |
TP3011 is a potent topoisomerase I inhibitor equipotent as SN38 and is an active metabolite of CH-0793076. | |||
T79263 |
Antitumor agent-102
|
Topoisomerase | DNA Damage/DNA Repair |
Antitumor agent-102(compound 10)是拓扑异构酶 I(topoisomerase I)抑制剂SN38与葡萄糖转运蛋白(glucose transporter)抑制剂缀合物,专门针对结直肠癌。相较于伊立替康,该化合物在肿瘤组织中可诱导游离SN38的更高浓度。 | |||
T69162 |
Ki23057
|
Others | Others |
Ki23057 is a a FGFR2 inhibitor, which enhances the chemosensitivity of drug-resistant gastric cancer cell lines when used in combination with chemotherapeutic drugs. Ki23057 might be therapeutically promising for treating drug-resistant gastric cancer cells, especially when used in combination with SN38, PTX, or VP16. The apoptosis process might be the main mechanism underlying the synergistic effect of these combinations. The ERCC1 and p53 genes may play an integral role in the synergism betwee... |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T1703 |
SN-38
7-乙基-10-羟基喜树碱,NK012,伊立替康杂质B,SN 38 |
DNA/RNA Synthesis; Topoisomerase; Autophagy; ADC Cytotoxin | Antibody-drug Conjugate/ADC Related; Autophagy; Cell Cycle/Checkpoint; DNA Damage/DNA Repair |
SN-38 (NK012) 是 DNA 拓扑异构酶 I (Topo I) 抑制剂 Irinotecan 的活性代谢产物,可以抑制 DNA 和 RNA 合成 (IC50=0.077/1.3 μM)。SN-38 具有抗肿瘤活性,可以诱导细胞自噬。 |